Clinical Trials Browser

Phase 2 × 3-ingenyl angelate × Dermatologic × Clear all

NCT01998984 2025-03-10

Efficacy and Safety of Ingenol Mebutate Gel 0.06% When Applied Once Daily for 2, 3 or 4 Consecutive Days to a Treatment Area of Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis

Phase 2 Completed

266 enrolled 15 charts

Keratosis, Actinic

NCT02354391 2019-03-26

Ingenol Mebutate (Picato®) With Methyl Aminolevulinate Photodynamic Therapy for the Treatment of Actinic Keratosis

Phase 2 Unknown

Keratosis, Actinic

NCT00375739 2016-01-28

Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses

Phase 2 Completed

Melanosis, Keratosis, Actinic

NCT00427050 2015-09-14

A Study to Determine the Optimal Tolerated Regime and Safety of PEP005 Topical Gel

Phase 2 Completed

Keratosis, Actinic

NCT00544297 2015-04-02

A Study to Examine the Safety and Toleration of PEP005 Topical Gel in Patients With Actinic Keratoses on the Top of the Hand

Phase 2 Completed

Keratosis, Actinic

NCT00107965 2015-03-25

Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Actinic Keratoses

Phase 2 Completed

Melanosis, Keratosis, Actinic

NCT00239135 2015-03-25

Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel

Phase 2 Completed

Keratosis, Melanosis, Keratosis, Actinic

NCT00852137 2015-03-06

A Study to Evaluate the Pharmacokinetics of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Applied in a Maximal Use Setting to the Dorsal Aspect of the Forearm in Patients With Actinic Keratosis

Phase 2 Completed

16 enrolled 9 charts

Keratosis, Actinic

NCT00108121 2015-01-19

Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Nodular Basal Cell Carcinoma

Phase 2 Completed

Carcinoma, Basal Cell

NCT01214564 2011-01-25

Study to Evaluate the Safety and Efficacy of PEP005(Ingenol Mebutate) Gel, 0.05%, in Patients With Seborrhoeic Keratosis

Phase 2 Completed

Keratosis, Seborrheic, Keratosis, Actinic

NCT00108134 2008-12-24

Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Superficial Basal Cell Carcinoma

Phase 2 Completed

Carcinoma, Basal Cell